Cost to bring biopharmaceutical assets in mid cap companies to market 2013-2020

This statistic shows the cost to bring a biopharmaceutical asset to market among mid-to-large cap biopharma companies from 2013 to 2020. According to the data, the cost to bring an asset to market was highest in 2018, with some 2.8 billion U.S. dollars.

本统计数据显示了2013年至2020年间，中等至大型生物制药公司将其生物制药资产推向市场所需的成本。根据数据，2018年将该资产推向市场的成本最高，约为28亿美元。